|Inkef Capital||Entrepreneurial Investor in Life Sciences and Technology||The Netherlands|
Shared risk or competition for emerging assets: How can we optimise the Pharma-VC relationship?
Lucas de Breed, PhD MBA, is an Investment Director at Inkef Capital, one of the leading VC firms in Europe, based in Amsterdam. He has 10+ years of international experience in all phases of drug development, particularly in oncology. During his time at Deallus Consulting, a global life sciences consulting firm, he was responsible for leading the oncology business and founded and managed the firm’s East Coast office in New York. Consequently, he helped co-found or advised half a dozen early-stage therapeutics, med tech and diagnostics companies in both New York and the Bay Area. He is currently also on the supervisory board of Scenic Biotechnology (Amsterdam), TM3 Therapeutics (Leiden), InteRNA Technologies (Utrecht) and CrowdyNews (Groningen/New York), and on the scientific advisory board of Phosplatin Therapeutics (New York) and on the board of non-profit QuantumLeap Healthcare Collaborative (San Francisco) .
Lucas holds a Ph.D. In Molecular Biology and Biochemistry from University College London and an MBA from Stanford University. He has also co-authored several scientific and industry papers.